JP2022529943A5 - - Google Patents
Info
- Publication number
- JP2022529943A5 JP2022529943A5 JP2021561663A JP2021561663A JP2022529943A5 JP 2022529943 A5 JP2022529943 A5 JP 2022529943A5 JP 2021561663 A JP2021561663 A JP 2021561663A JP 2021561663 A JP2021561663 A JP 2021561663A JP 2022529943 A5 JP2022529943 A5 JP 2022529943A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- type
- composition according
- directed
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025032100A JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962920140P | 2019-04-15 | 2019-04-15 | |
| US62/920,140 | 2019-04-15 | ||
| PCT/US2020/028296 WO2020214690A1 (en) | 2019-04-15 | 2020-04-15 | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032100A Division JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529943A JP2022529943A (ja) | 2022-06-27 |
| JP2022529943A5 true JP2022529943A5 (cg-RX-API-DMAC7.html) | 2023-04-19 |
Family
ID=70554222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561663A Pending JP2022529943A (ja) | 2019-04-15 | 2020-04-15 | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
| JP2025032100A Pending JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032100A Pending JP2025084914A (ja) | 2019-04-15 | 2025-02-28 | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11136353B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3955957A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022529943A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210153092A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113993540A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020258384B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3136602A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020214690A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399219B2 (en) * | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| US20240076355A1 (en) * | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| KR20240021943A (ko) * | 2021-06-18 | 2024-02-19 | 남미 테라퓨틱스, 인크. | 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법 |
| US20240390506A1 (en) * | 2021-09-28 | 2024-11-28 | Suzhou Fuse Biosciences Limited | Immunoconjugates containing tnf-alpha and related methods and compositions thereof |
| CN115057946B (zh) * | 2022-06-30 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用 |
| WO2024181570A1 (ja) | 2023-03-02 | 2024-09-06 | 大鵬薬品工業株式会社 | 抗cd138抗体を含む抗体薬物複合体 |
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
| WO2026117686A1 (en) | 2024-11-27 | 2026-06-04 | Nammi Therapeutics, Inc. | FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| KR20020018197A (ko) | 1999-05-19 | 2002-03-07 | 추후보정 | Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| AU2004213565A1 (en) | 2003-02-18 | 2004-09-02 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
| PT2418220T (pt) | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| KR100845354B1 (ko) | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항-ctla-4 항체의 용도 |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| US20080064862A1 (en) | 2004-12-29 | 2008-03-13 | Avigenics, Inc. | Transgene expression in a avians |
| KR20080026135A (ko) | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| EP2116768B1 (en) | 2008-05-09 | 2016-07-27 | Alstom Technology Ltd | Burner |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CN102413843A (zh) | 2009-03-05 | 2012-04-11 | 阿森迪斯药物股份有限公司 | 干扰素α载体前药 |
| WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
| HRP20150664T1 (hr) | 2010-12-03 | 2015-07-31 | Adamed Sp. Z O.O. | Antikancerogeni fuzijski protein |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| EP2984171A2 (en) | 2013-04-10 | 2016-02-17 | Skau Aps | Peptides having immune suppresive domains for transfection |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| US10435695B2 (en) | 2016-09-08 | 2019-10-08 | The Government of the United States of America, as represented by the Secretary of Homeland Security | Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences |
| JP2020528878A (ja) | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
-
2020
- 2020-04-15 CA CA3136602A patent/CA3136602A1/en active Pending
- 2020-04-15 AU AU2020258384A patent/AU2020258384B2/en active Active
- 2020-04-15 US US16/849,889 patent/US11136353B2/en active Active
- 2020-04-15 WO PCT/US2020/028296 patent/WO2020214690A1/en not_active Ceased
- 2020-04-15 CN CN202080044080.4A patent/CN113993540A/zh active Pending
- 2020-04-15 KR KR1020217036953A patent/KR20210153092A/ko active Pending
- 2020-04-15 JP JP2021561663A patent/JP2022529943A/ja active Pending
- 2020-04-15 EP EP20724309.8A patent/EP3955957A1/en active Pending
-
2021
- 2021-09-02 US US17/465,727 patent/US11795198B2/en active Active
-
2023
- 2023-09-14 US US18/467,206 patent/US12162958B2/en active Active
-
2025
- 2025-02-28 JP JP2025032100A patent/JP2025084914A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025084914A (ja) | がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| JP2021521822A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512043A5 (cg-RX-API-DMAC7.html) | ||
| JP2020531043A5 (cg-RX-API-DMAC7.html) | ||
| JP2022520998A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520092A5 (cg-RX-API-DMAC7.html) | ||
| JP2021512151A5 (cg-RX-API-DMAC7.html) | ||
| JP2019506869A5 (cg-RX-API-DMAC7.html) | ||
| JP2003523771A5 (cg-RX-API-DMAC7.html) | ||
| EP4277707A1 (en) | Interferon prodrugs and methods of making and using the same | |
| CN106714831A (zh) | 新的抗‑rnf43抗体和使用方法 | |
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| JP2023123649A5 (cg-RX-API-DMAC7.html) | ||
| CA2755686A1 (en) | Methods and compositions for bi-specific targeting of cd19/cd22 | |
| JP2019524640A5 (cg-RX-API-DMAC7.html) | ||
| Bera et al. | Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JP2023544143A5 (cg-RX-API-DMAC7.html) | ||
| HRP20161449T1 (hr) | Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena | |
| JP2024510811A5 (cg-RX-API-DMAC7.html) | ||
| JP2022548364A5 (cg-RX-API-DMAC7.html) |